Related Experiment Video
Updated: Apr 18, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Can we optimise the TB response amid funding constraints using evidence-based, cost-effective strategies
M A Yassin1, A Rashid1,2, E Wandwalo1
1The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
Background:
Despite progress in the TB response, including through the Global Fund's catalytic efforts, funding gaps and inefficiencies threaten efforts to sustain gains and accelerate the TB response. Recent donor funding cuts have further strained programmes in low- and middle-income countries.
Methods:
A mixed-method, combining desk and literature review and key informant interviews with national TB programme stakeholders, technical experts, and partners, was conducted using standardised tools. Findings were triangulated to identify strategies/approaches that improve efficiency, access, and outcomes.
Results:
We identified cost-effective strategies that optimise resources and tools to sustain and expand access to services amid declining funding. Strategies to enhance efficiency include screening using digital X-rays (with artificial intelligence), testing samples (including pooled samples) with molecular diagnostics, decentralising care, engaging communities and private sector, and integrating TB services with broader health system. Cost-saving measures involve integrated sample transport and supervision, integrating TB with other diseases such as HIV, diabetes, and undernutrition, task shifting, shorter treatment regimens, digital tools, and e-learning. Emphasis was also placed on innovative financing, domestic resource mobilisation, and country ownership.
Conclusion:
Accelerating to end TB requires integrated and efficient strategies, innovative financing, and increased domestic resources, ensuring provision of equitable and high-quality TB services while strengthening the health system and ensuring sustainability.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Methods of Medium Optimization

